42,15EUR | -0,20 EUR | -0,47 %
DAX+0,57 % EUR/USD+0,20 % Gold+0,44 % Öl (Brent)+1,45 %

Mannkind, Game-Chancer in Sachen Diabetik? (Seite 543)

ISIN: US56400P7069 | WKN: A2DMZL | Symbol: MNKD
-3,86 %
-0,048 EUR

Begriffe und/oder Benutzer


Es scheint so als jetzt Ultra fast acting als Patent erteilt wurde, wichtig!

United States Patent 10,307,464
Boss , et al. June 4, 2019
Use of ultrarapid acting insulin


Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Inventors: Boss; Anders Hasager (Princeton, NJ), Petrucci; Richard (New Canaan, CT)
Name City State Country Type

MannKind Corporation
Assignee: MannKind Corporation (Westlake Village, CA)
Family ID: 1000004056698
Appl. No.: 15/300,239
Filed: March 27, 2015
PCT Filed: March 27, 2015
PCT No.: PCT/US2015/022956
371(c)(1),(2),(4) Date: September 28, 2016
PCT Pub. No.: WO2015/148905
PCT Pub. Date: October 01, 2015
Prior Publication Data

Document Identifier Publication Date
US 20170189492 A1 Jul 6, 2017

Current U.S. Class: 1/1
Current CPC Class: A61K 38/28 (20130101); A61K 9/007 (20130101); A61K 9/0075 (20130101); A61K 31/155 (20130101); A61K 31/155 (20130101); A61K 9/0019 (20130101); A61K 2300/00 (20130101)
Current International Class: A61K 38/28 (20060101); A61K 31/155 (20060101); A61K 9/00 (20060101)
Ergänzend dazu habe ich gelesen, dass auch CBD Produkte, die aus Hanf gewonnen werden, gegen Diabetes helfen können. Ein Beispiel was ich meine ist dieses Ambrosia CBD-Liquid von cbdkaufen.com. Es ist eine Überlegung wert, in entsprechende Unternehmen einzusteigen, da das Geschäft mit CBD aktuell boomt und spätestens wenn die Grünen uns regieren, wird es noch mehr im Trend sein.
Top news, eigentlich müssten die scripts beim Zehnfachen sein, bei solchen Daten:

MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
GlobeNewswire•June 9, 2019

WESTLAKE VILLAGE, Calif., June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California.

Poster 1350-P: Safety and Pharmacokinetics of Technosphere Insulin in Pediatric Patients

MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10. This study is the first step in preparation for a phase 3 safety and efficacy study.

Poster Highlights:

In pediatric patients, the rapid rise in insulin concentrations corresponded with early postprandial glucose control within the first hour post-dose. The profile is similar to that previously observed in adults.
Consistent with its safety profile in adults, Afrezza was generally well-tolerated in pediatric patients; most treatment emergent adverse events were of mild severity, and no severe hypoglycemia was observed.
These data will help guide the finalization of the protocol for a phase 3 safety and efficacy study.

“We are excited to share the progress of the ongoing pediatric study program,” said David Kendall, M.D., Chief Medical Officer of MannKind. “As is well known, type 1 diabetes is often diagnosed in children and adolescents, and these individuals will continue to require insulin therapy throughout their lives. Evaluating as quickly as possible the potential use of Afrezza in children and adolescents as an option for mealtime insulin therapy is a top priority for MannKind.”

Poster 136-LB: Effective Treatment of T2D Patients Uncontrolled on Multiple Diabetes Medications by Adding Afrezza® Mealtime Ultra-Rapid Insulin

Dr. Philip Levin and colleagues presented data from an independent study supported and funded by MannKind. Dr. Levin presented late-breaking clinical data on interim results of a study² showing how a fixed titration schedule can be implemented to achieve better time in range and reduction of overall A1c.

Late Breaking Poster Highlights:

Enrolled adult patients with uncontrolled type 2 diabetes on two or more therapies (orals/ basal/ GLPs) – with the addition of Afrezza at all meals by means of a rapid and ongoing titration protocol
Observed a mean decrease in A1c of ~1.6% (all subjects with A1c reduction over 12 weeks of study)
93% (13 of 14 subjects) achieved A1c below 8% (mean baseline A1c 9.1%)
Reduced hyperglycemia (>250mg/dL) by 74%
Increased time in range more than 75%; daily glucose decreased by ~50 mg/dL as measured by blinded continuous glucose monitoring
No significant difference in rates of hypoglycemia with the addition of Afrezza

“We are pleased to share the interim analysis from our independent investigator-initiated trial of Afrezza therapy. These preliminary data significantly advance our understanding of the potential clinical benefits and practical use of Afrezza therapy for those living with type 2 diabetes,” stated Philip Levin, M.D. of Bay West Endocrinology Associates and MODEL Clinical Research in Baltimore, MD. “Data generated to this point are encouraging and support the use of Afrezza as prandial therapy earlier in the treatment of type 2 diabetes.”

Oral Abstract
151-OR: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog

MannKind investigators also shared data at an oral presentation³ using mixed meal tolerance testing to assess glucose control, Afrezza dosing and overall safety in a cohort of individuals with type 1 diabetes.

Oral Presentation Highlights:

When compared to rapid acting injected insulin, Afrezza provided significantly better glucose control in the first two hours following the meal.
Even when adjusting the dose of Afrezza using up to two times the dose of injected insulin aspart, Afrezza treatment was associated with lower rates of overall and level 2 hypoglycemia - an observation that was particularly evident in the late (>2 hour) post-meal period.

Dr. Anne Peters, Clinical Professor of Medicine at the Keck School of Medicine at USC and Director of the USC Westside Center for Diabetes Care noted that “the improved post-meal glucose levels and lower rates of low blood sugars seen in this study of individuals with type 1 diabetes support my growing clinical experience. The presentation of these data provides further evidence that proper dosing of Afrezza has the potential to safely and effectively get more patients into target range at meal times.”

About Afrezza®

Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients ma
Antwort auf Beitrag Nr.: 60.769.987 von Magnetfeldfredy am 09.06.19 22:00:46🙃Lange kann man die nicht mehr unten halten
Antwort auf Beitrag Nr.: 60.771.355 von lobberland am 10.06.19 10:36:32Das dürfte der Durchbruch sein nach Norden 🤗
bleibt bei mie Frage

warum nur steigt die Zahl NTX und vor allem die der Wiedrkäufer nucht deutlicher an

IMO: die Ärzte WOLLEN nicht verschreiben.

und: kann ich komplett von den Spritzen umsteigen auf AFREZZA

DAS wäre es doch

weg mit den Spritzen.

Nur in halieren
Dieser Beitrag wurde von CommunityAssistance moderiert. Grund: Beschäftigung mit Usern - bitte kehren Sie zum Threadthema zurück.
Antwort auf Beitrag Nr.: 60.771.892 von pegasusorion am 10.06.19 12:06:49Moin- und danke

Wünsche Mannkind Erfolg

jetzt sollte doch bitte ein short squeeze kommen

der der enorm hohen Zahl an shorts

würde mich freuen-haben es wirklich verdient IMO
Vorbörsliches Plus von knapp 20% schmilzt leider dahin...

Wenn hier mal ein größerer Fonds einsteigen würde oder sich Big Pharma an Mannkind beteiligt, können sich die Shorts warmanziehen... 🔥

Beitrag zu dieser Diskussion schreiben